Position in TNGX
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$6,206,891
+$5,581,070 QoQ
Shares Held
198,557
+563.7% QoQ
Ownership
0.118%
of shares outstanding
% of Portfolio
1.67%
of 13F equity value
Holder Rank
#92
of 247 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Atle Fund Management AB holds $141,162,145 across 21 Biotechnology names. TNGX ranks #12 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
73,077 | $13,685,860 | |
| 2 | MIRM |
Mirum Pharmaceuticals, Inc.
|
100,807 | $11,801,475 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
137,131 | $10,873,116 | |
| 4 | ONC |
BeOne Medicines Ltd.
|
35,180 | $10,025,244 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
19,131 | $9,502,941 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
124,707 | $9,288,177 | |
| 7 | KRYS |
Krystal Biotech, Inc.
|
24,019 | $8,927,141 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
248,848 | $8,433,458 |
All Filings in TNGX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,206,891 | 198,557 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $625,821 | 29,915 | Shares | Sole | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||